S-777469, a Novel Cannabinoid Type 2 Receptor Agonist, Suppresses Itch-Associated Scratching Behavior in Rodents through Inhibition of Itch Signal Transmission

  title={S-777469, a Novel Cannabinoid Type 2 Receptor Agonist, Suppresses Itch-Associated Scratching Behavior in Rodents through Inhibition of Itch Signal Transmission},
  author={Takayo Haruna and Masahiko Soga and Yasuhide Morioka and Ichiro Hikita and Kinichi Imura and Yoko Furue and Mina Yamamoto and Chihiro Imura and Minoru Ikeda and Akira Yamauchi and Masashi Deguchi and Michitaka Shichijo and Akinori Arimura and Kiyoshi Yasui},
  pages={95 - 103}
We have previously reported that S-777469 [1-([6-ethyl-1-(4-fluorobenzyl)-5-methyl-2-oxo-1,2-dihydropyridine-3-carbonyl]amino)-cyclohexanecarboxylic acid], a novel cannabinoid type 2 receptor (CB2) agonist, significantly suppressed compound 48/80-induced scratching behavior in mice in a dose-dependent manner when it was administered orally. Here, we demonstrated that the inhibitory effects of S-777469 on compound 48/80-induced scratching behavior are reversed by pretreatment with SR144528, a… 

Figures from this paper

The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice
The results suggest that S-777469 inhibits skin inflammation in mice by blocking the activities of 2-AG.
The Effects of the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin, Cannabinoid Agonist WIN 55,212-2, and Nitric Oxide Synthase Inhibitor Nω-Nitro-L-Arginine Methyl Ester Hydrochloride on the Serotonin and Dry Skin-Induced Itch
The results demonstrate that Hsp 90 may play a role in the peripheral pathway of pruritus, and cannabinoid agonists and Hsp90 inhibitors can be used together in the treatment ofPruritus.
The false-positive responses of analgesic drugs to the intradermal serotonin- and compound 48/80-induced scratches as an animal model of itch.
The data suggests that intradermal pruritogen-induced scratching models may not discriminate pain and itch sensations and give false positive results when standard analgesic drugs are used.
Potential Pro-Inflammatory Effect of Vitamin E Analogs through Mitigation of Tetrahydrocannabinol (THC) Binding to the Cannabinoid 2 Receptor
The role of vitamin E in limiting the effect of THCs and its implications on the reported pathology of EVALI are discussed.
Systemic and spinal administration of FAAH, MAGL inhibitors and dual FAAH/MAGL inhibitors produce antipruritic effect in mice
The results suggest that endocannabinoid-degrading enzymes FAAH and MAGL are involved in pruritic process at spinal level, at least in part through spinal site of action.
Current evidence of cannabinoid‐based analgesia obtained in preclinical and human experimental settings
Human evidence presently provides only reluctant support for a broad clinical use of cannabinoid‐based medications in pain therapy, based on preclinical and human experimental research summarized in this review.
The Structure–Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation
This perspective will examine the classical cannabinoids, with particular emphasis on the structure–activity relationship of five regions: C3 side chain, phenolic hydroxyl, aromatic A-ring, pyran B- ring, and cyclohexenyl C-ring.
Cannabinoid Signaling in the Skin: Therapeutic Potential of the “C(ut)annabinoid” System
An overview of the available skin-relevant endo- and phytocannabinoid literature is given with a special emphasis on the putative translational potential, and to highlight promising future research directions as well as existing challenges.
Double blinded, vehicle controlled, crossover study on the efficacy of a topical endocannabinoid membrane transporter inhibitor in atopic Beagles
Test the effects of a newly developed topical endocannabinoid membrane transporter inhibitor (WOL067-531, 1% gel) on pruritus and dermatitis in a canine model of AD and found it minimized allergic flares and pruritis.


Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging
  • B. Yao, G. Hsieh, M. Meyer
  • Biology, Chemistry
    Journal of Pharmacology and Experimental Therapeutics
  • 2009
The identification of A-836339 as a potent and selective CB2 agonist as characterized in in vitro pharmacological assays and in in vivo models of pain and central nervous system (CNS) behavior models and investigation of the role of CB2 receptor modulation for treatment of pain in preclinical animal models are reported.
5-Hydroxytryptamine (5-HT)2 Receptor Involvement in Acute 5-HT-Evoked Scratching but Not in Allergic Pruritus Induced by Dinitrofluorobenzene in Rats
Intradermal injection of α-methylserotonin, a 5-HT2 receptor agonist, elicited scratching behavior in a dose-dependent manner, indicating that acute5-HT-induced scratching is mediated via peripheral 5- HT2 receptors.
CB2 receptor‐mediated antihyperalgesia: possible direct involvement of neural mechanisms
It is suggested that CB2 agonists may elicit their analgesic effect by acting not only at non‐neuronal peripheral sites but also at neural level, making CB2 an attractive target for chronic pain treatment.
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor.
  • L. Hanuš, A. Breuer, E. Fride
  • Biology
    Proceedings of the National Academy of Sciences of the United States of America
  • 1999
HU-308 reduces blood pressure, blocks defecation, and elicits anti-inflammatory and peripheral analgesic activity, demonstrating the feasibility of discovering novel nonpsychotropic cannabinoids that may lead to new therapies for hypertension, inflammation, and pain.
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.
The authors' results suggest that the six-membered lactone pharmacophore is critical for CB2 receptor selectivity, and synthesized benzo-6-one analogs possessing high affinity and selectivity for this receptor are CB2 agonists.
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS
  • M. Ibrahim, H. Deng, T. Malan
  • Biology, Medicine
    Proceedings of the National Academy of Sciences of the United States of America
  • 2003
AM1241 dose-dependently reversed tactile and thermal hypersensitivity produced by ligation of the L5 and L6 spinal nerves in rats, demonstrating a mechanism leading to the inhibition of pain, one that targets receptors localized exclusively outside the CNS.
Functional Selectivity in CB2 Cannabinoid Receptor Signaling and Regulation: Implications for the Therapeutic Potential of CB2 Ligands
Receptor internalization increases the flexibility and scope of G protein-coupled receptor (GPCR) signaling. CB1 and CB2 cannabinoid receptors undergo internalization after sustained exposure to
Involvement of leukotriene B(4) in substance P-induced itch-associated response in mice.
Results suggest that leukotriene B(4) receptor antagonist and 5-lipoxygenase inhibitor may be novel antipruritic drugs and keratinocytes play an important role in substance P-induced itch-scratch response in mice.
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation.
It is demonstrated that activation of cannabinoid CB2 receptors is sufficient to suppress neuronal activity at central levels of processing in the spinal dorsal horn and this findings are consistent with the ability of AM1241 to normalize nociceptive thresholds and produce antinociception in inflammatory pain states.
Regulation of peripheral cannabinoid receptor CB2 phosphorylation by the inverse agonist SR 144528. Implications for receptor biological responses.
It is shown that CB2 is constitutively active, phosphorylated, and internalized at the basal level, and inverse agonist SR 144528 treatment completely inhibited this phosphorylation state, leading to an up-regulated CB2 receptor level at the cell surface, and enhanced cannabinoid agonist sensitivity for mitogen-activated protein kinase activation of Chinese hamster ovary-CB2 cells.